TrialOpen Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
Trial details
- Registry ID
- NCT02143973
- Phase
- Phase 2, Phase 3
Drug research
nalbuphine HCl ER
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as nalbuphine
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic PruritusNCT02143973 | Trevi Therapeutics | Phase 2, Phase 3 | Completed | 2016-01Actual |
| Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo NodularisNCT02174432 | Trevi Therapeutics | Phase 2, Phase 3 | Completed | 2017-09-03Actual |
Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
Trial details
- Registry ID
- NCT02174432
- Phase
- Phase 2, Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |